Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| OnKure Therapeutics, Inc.RPHM · Entity 6550 | VP of Finance & Administration | December 09, 2022 | December 13, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
OnKure Therapeutics, Inc.
Report date December 09, 2022 · Filed December 13, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.80 · Expires 2032-12-08 | Direct | 90,000 |
Reported balance
After 2022-12-09 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-12-09 · Grant · Acquired 90,000 · Balance 90,000 F2: The shares vest in a series of equal quarterly installments measured from December 9, 2022 subject to Reporting Person's Continuous Service (as defined in the Issuer's 2021 Equity Incentive Plan) as of each such vesting date. |
| Common StockSEC Table I · non-derivative | Direct | 20,600 |
Reported balance
Holding disclosure · report date 2022-12-09 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 20,600 F1: Includes 1,600 shares acquired under the Issuer's 2021 Employee Stock Purchase Plan (the "Plan") on June 8, 2022 and 4,000 shares acquired under the Plan on December 8, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 1,600 shares acquired under the Issuer's 2021 Employee Stock Purchase Plan (the "Plan") on June 8, 2022 and 4,000 shares acquired under the Plan on December 8, 2022.
F2: The shares vest in a series of equal quarterly installments measured from December 9, 2022 subject to Reporting Person's Continuous Service (as defined in the Issuer's 2021 Equity Incentive Plan) as of each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 09, 2022 Filed Dec 13, 2022 18:13 UTC | OnKure Therapeutics, Inc. RPHM · Entity 6550 | GrantStock option (right to buy) · Derivative | 90,000 | $0.00 Strike: $1.80 | $0.00 |
DisclosureSEC source: 0001209191-22-061044 · doc4.xml · derivative · entry 2 Lam Jennifer · CIK 0001919598 · VP of Finance & Administration 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2032-12-08 F2 · derivative.exercise_date: The shares vest in a series of equal quarterly installments measured from December 9, 2022 subject to Reporting Person's Continuous Service (as defined in the Issuer's 2021 Equity Incentive Plan) as of each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.